{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:37:19Z","timestamp":1759624639969,"version":"build-2065373602"},"reference-count":3,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.eururo.2022.02.011","type":"journal-article","created":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T15:39:27Z","timestamp":1645285167000},"page":"621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Re: Abiraterone Acetate and Prednisolone With or Without Enzalutamide for High-risk Non-metastatic Prostate Cancer: A Meta-analysis of Primary Results from Two Randomized Controlled Phase 3 Trials of the STAMPEDE Platform Protocol"],"prefix":"10.1016","volume":"81","author":[{"given":"Viktor","family":"Gr\u00fcnwald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten-Henning","family":"Ohlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2022.02.011_b0005","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2022.02.011_b0010","first-page":"737","article-title":"How to treat prostate cancer with androgen deprivation and minimize cardiovascular risk: a therapeutic tightrope","volume":"3","author":"Narayan","year":"2021","journal-title":"J Am Coll Cardiol CardioOncol"},{"key":"10.1016\/j.eururo.2022.02.011_b0015","doi-asserted-by":"crossref","first-page":"e2138550","DOI":"10.1001\/jamanetworkopen.2021.38550","article-title":"Performance of a prostate-specific membrane antigen positron emission tomography\/computed tomography\u2013derived risk-stratification tool for high-risk and very high-risk prostate cancer","volume":"4","author":"Xiang","year":"2021","journal-title":"JAMA Netw Open"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283822016487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283822016487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:11:14Z","timestamp":1759583474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283822016487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":3,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0302283822016487"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2022.02.011","relation":{},"ISSN":["0302-2838"],"issn-type":[{"type":"print","value":"0302-2838"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re: Abiraterone Acetate and Prednisolone With or Without Enzalutamide for High-risk Non-metastatic Prostate Cancer: A Meta-analysis of Primary Results from Two Randomized Controlled Phase 3 Trials of the STAMPEDE Platform Protocol","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2022.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}